Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
131 hedge funds and large institutions have $694M invested in Intra-Cellular Therapies Inc. in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 51 increasing their positions, 44 reducing their positions, and 13 closing their positions.
72% more call options, than puts
Call options by funds: $35.4M | Put options by funds: $20.5M
16% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 44
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 131 → 131 (0)
16% less capital invested
Capital invested by funds: $829M → $694M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$24.2M |
| 2 |
Millennium Management
New York
|
+$7.65M |
| 3 |
SC
Samlyn Capital
New York
|
+$6.82M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.39M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$28.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.14M |
| 3 |
Renaissance Technologies
New York
|
-$4.46M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.81M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$2.78M |
ITCI Hedge Fund Activity: Q2 2018 in Review
131 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2018, worth a combined $694M — down 16% from $829M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ITCI positions and 13 closed out — a net gain of 1 holder — while 51 added to existing stakes and 44 trimmed.
The largest buyer was Schroder Investment Management Group, opening a new position worth an estimated $24.2M. The largest seller was PointState Capital, cutting an estimated $28.3M.
- 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $694M of Intra-Cellular Therapies Inc. stock for Q2 2018, down 16% quarter-over-quarter.
- 14 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2018 and 13 closed out, a net change of +1 holder.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2018 was Schroder Investment Management Group, an estimated $24.2M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2018 was PointState Capital, an estimated $28.3M sold.
Based on aggregated 13F filings for Q2 2018.